Helen Collins's most recent trade in Enliven Therapeutics Inc was a trade of 5,000 shares done at an average price of $2.5 . Disclosure was reported to the exchange on Oct. 19, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Enliven Therapeutics Inc | Dr. Helen Collins, M.D. | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 19 Oct 2026 | 5,000 | 30,000 | - | 2.5 | 12,400 | - |
| Enliven Therapeutics Inc | Dr. Helen Collins, M.D. | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 38.47 per share. | 19 Oct 2026 | 5,000 | 25,000 | - | 38.5 | 192,342 | - |
| Enliven Therapeutics Inc | Dr. Helen Collins, M.D. | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 17 Sep 2026 | 5,000 | 30,000 | - | 2.5 | 12,400 | Common Stock |
| Enliven Therapeutics Inc | Dr. Helen Collins, M.D. | CHIEF MEDICAL OFFICER | 17 Sep 2026 | 5,000 | 106,268 | - | - | Stock Option (right to buy) | ||
| Enliven Therapeutics Inc | Dr. Helen Collins, M.D. | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 50.03 per share. | 17 Sep 2026 | 2,916 | 27,084 | - | 50.0 | 145,891 | Common Stock |
| Enliven Therapeutics Inc | Dr. Helen Collins, M.D. | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 50.71 per share. | 17 Sep 2026 | 1,844 | 25,240 | - | 50.7 | 93,507 | Common Stock |
| Enliven Therapeutics Inc | Dr. Helen Collins, M.D. | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 51.48 per share. | 17 Sep 2026 | 240 | 25,000 | - | 51.5 | 12,356 | Common Stock |
| Enliven Therapeutics Inc | Dr. Helen Collins, M.D. | CHIEF MEDICAL OFFICER | 17 Aug 2026 | 5,000 | 111,268 | - | - | Stock Option (right to buy) | ||
| Enliven Therapeutics Inc | Dr. Helen Collins, M.D. | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 17 Aug 2026 | 5,000 | 30,000 | - | 2.5 | 12,400 | Common Stock |
| Enliven Therapeutics Inc | Dr. Helen Collins, M.D. | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 58.37 per share. | 17 Aug 2026 | 3,900 | 26,100 | - | 58.4 | 227,650 | Common Stock |
| Enliven Therapeutics Inc | Dr. Helen Collins, M.D. | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 59.35 per share. | 17 Aug 2026 | 1,100 | 25,000 | - | 59.3 | 65,281 | Common Stock |
| Enliven Therapeutics Inc | Dr. Helen Collins, M.D. | CHIEF MEDICAL OFFICER | 17 Jul 2026 | 5,000 | 116,268 | - | - | Stock Option (right to buy) | ||
| Enliven Therapeutics Inc | Dr. Helen Collins, M.D. | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 17 Jul 2026 | 5,000 | 30,000 | - | 2.5 | 12,400 | Common Stock |
| Enliven Therapeutics Inc | Dr. Helen Collins, M.D. | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 53.42 per share. | 17 Jul 2026 | 2,184 | 25,063 | - | 53.4 | 116,669 | Common Stock |
| Enliven Therapeutics Inc | Dr. Helen Collins, M.D. | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 52.39 per share. | 17 Jul 2026 | 2,063 | 27,247 | - | 52.4 | 108,085 | Common Stock |
| Enliven Therapeutics Inc | Dr. Helen Collins, M.D. | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 51.55 per share. | 17 Jul 2026 | 459 | 29,310 | - | 51.5 | 23,660 | Common Stock |
| Enliven Therapeutics Inc | Dr. Helen Collins, M.D. | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 50.06 per share. | 17 Jul 2026 | 231 | 29,769 | - | 50.1 | 11,563 | Common Stock |
| Enliven Therapeutics Inc | Dr. Helen Collins, M.D. | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 53.92 per share. | 17 Jul 2026 | 63 | 25,000 | - | 53.9 | 3,397 | Common Stock |
| Enliven Therapeutics Inc | Dr. Helen Collins, M.D. | CHIEF MEDICAL OFFICER | 17 Jun 2026 | 5,000 | 121,268 | - | - | Stock Option (right to buy) | ||
| Enliven Therapeutics Inc | Dr. Helen Collins, M.D. | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 17 Jun 2026 | 5,000 | 30,000 | - | 2.5 | 12,400 | Common Stock |
| Enliven Therapeutics Inc | Dr. Helen Collins, M.D. | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 43.87 per share. | 17 Jun 2026 | 2,599 | 26,133 | - | 43.9 | 114,018 | Common Stock |
| Enliven Therapeutics Inc | Dr. Helen Collins, M.D. | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 42.83 per share. | 17 Jun 2026 | 1,268 | 28,732 | - | 42.8 | 54,305 | Common Stock |
| Enliven Therapeutics Inc | Dr. Helen Collins, M.D. | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 44.74 per share. | 17 Jun 2026 | 1,133 | 25,000 | - | 44.7 | 50,694 | Common Stock |
| Kura Oncology Inc | Dr. Helen Collins, M.D. | Director | 04 Jun 2026 | 35,000 | 35,000 | - | - | Option to purchase common stock | ||
| Enliven Therapeutics Inc | Dr. Helen Collins, M.D. | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 18 May 2026 | 5,000 | 30,000 | - | 2.5 | 12,400 | Common Stock |
| Enliven Therapeutics Inc | Dr. Helen Collins, M.D. | CHIEF MEDICAL OFFICER | 18 May 2026 | 5,000 | 126,268 | - | - | Stock Option (right to buy) | ||
| Enliven Therapeutics Inc | Dr. Helen Collins, M.D. | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 39.53 per share. | 18 May 2026 | 3,475 | 26,525 | - | 39.5 | 137,381 | Common Stock |
| Enliven Therapeutics Inc | Dr. Helen Collins, M.D. | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 40.25 per share. | 18 May 2026 | 1,302 | 25,223 | - | 40.2 | 52,402 | Common Stock |
| Enliven Therapeutics Inc | Dr. Helen Collins, M.D. | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 41.21 per share. | 18 May 2026 | 223 | 25,000 | - | 41.2 | 9,189 | Common Stock |
| Enliven Therapeutics Inc | Dr. Helen Collins, M.D. | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 17 Apr 2026 | 5,000 | 30,000 | - | 2.5 | 12,400 | Common Stock |
| Enliven Therapeutics Inc | Dr. Helen Collins, M.D. | CHIEF MEDICAL OFFICER | 17 Apr 2026 | 5,000 | 131,268 | - | - | Stock Option (right to buy) | ||
| Enliven Therapeutics Inc | Dr. Helen Collins, M.D. | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 48.06 per share. | 17 Apr 2026 | 2,441 | 25,000 | - | 48.1 | 117,303 | Common Stock |
| Enliven Therapeutics Inc | Dr. Helen Collins, M.D. | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 47.39 per share. | 17 Apr 2026 | 2,419 | 27,441 | - | 47.4 | 114,635 | Common Stock |
| Enliven Therapeutics Inc | Dr. Helen Collins, M.D. | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 45.81 per share. | 17 Apr 2026 | 140 | 29,860 | - | 45.8 | 6,413 | Common Stock |
| Enliven Therapeutics Inc | Dr. Helen Collins, M.D. | CHIEF MEDICAL OFFICER | 25 Mar 2026 | 40,000 | 136,268 | - | - | Stock Option (right to buy) | ||
| Enliven Therapeutics Inc | Dr. Helen Collins, M.D. | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 35.10 per share. | 25 Mar 2026 | 40,000 | 25,000 | - | 35.1 | 1,404,024 | Common Stock |
| Enliven Therapeutics Inc | Dr. Helen Collins, M.D. | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 25 Mar 2026 | 40,000 | 65,000 | - | 2.5 | 99,200 | Common Stock |
| Enliven Therapeutics Inc | Dr. Helen Collins, M.D. | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 17 Mar 2026 | 5,000 | 30,000 | - | 2.5 | 12,400 | Common Stock |
| Enliven Therapeutics Inc | Dr. Helen Collins, M.D. | CHIEF MEDICAL OFFICER | 17 Mar 2026 | 5,000 | 176,268 | - | - | Stock Option (right to buy) | ||
| Enliven Therapeutics Inc | Dr. Helen Collins, M.D. | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 27.76 per share. | 17 Mar 2026 | 5,000 | 25,000 | - | 27.8 | 138,800 | Common Stock |
| Enliven Therapeutics Inc | Dr. Helen Collins, M.D. | CHIEF MEDICAL OFFICER | 09 Mar 2026 | 29,871 | 191,397 | - | - | Stock Option (right to buy) | ||
| Enliven Therapeutics Inc | Dr. Helen Collins, M.D. | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 30.02 per share. | 09 Mar 2026 | 29,871 | 25,000 | - | 30.0 | 896,811 | Common Stock |
| Enliven Therapeutics Inc | Dr. Helen Collins, M.D. | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 09 Mar 2026 | 29,871 | 54,871 | - | 2.5 | 74,080 | Common Stock |
| Enliven Therapeutics Inc | Dr. Helen Collins, M.D. | CHIEF MEDICAL OFFICER | 09 Mar 2026 | 10,129 | 181,268 | - | - | Stock Option (right to buy) | ||
| Enliven Therapeutics Inc | Dr. Helen Collins, M.D. | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 30.19 per share. | 09 Mar 2026 | 10,129 | 25,000 | - | 30.2 | 305,827 | Common Stock |
| Enliven Therapeutics Inc | Dr. Helen Collins, M.D. | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 09 Mar 2026 | 10,129 | 35,129 | - | 2.5 | 25,120 | Common Stock |
| Enliven Therapeutics Inc | Dr. Helen Collins, M.D. | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 17 Feb 2026 | 45,000 | 70,000 | - | 2.5 | 111,600 | Common Stock |
| Enliven Therapeutics Inc | Dr. Helen Collins, M.D. | CHIEF MEDICAL OFFICER | 17 Feb 2026 | 45,000 | 221,268 | - | - | Stock Option (right to buy) | ||
| Enliven Therapeutics Inc | Dr. Helen Collins, M.D. | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 26.17 per share. | 17 Feb 2026 | 45,000 | 25,000 | - | 26.2 | 1,177,862 | Common Stock |
| Enliven Therapeutics Inc | Dr. Helen Collins, M.D. | CHIEF MEDICAL OFFICER | 12 Feb 2026 | 150,000 | 150,000 | - | - | Stock Option (right to buy) | ||
| Enliven Therapeutics Inc | Dr. Helen Collins, M.D. | CHIEF MEDICAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2026 | 25,000 | 25,000 | - | 0 | Common Stock | |
| IO Biotech Inc | Helen Collins | Director | 05 Jun 2025 | 35,144 | 35,144 | - | - | Stock Option (Right to Buy) | ||
| Kura Oncology Inc | Dr. Helen Collins, M.D. | Director | 05 Jun 2025 | 28,500 | 28,500 | - | - | Option to purchase common stock | ||
| Enliven Therapeutics Inc | Dr. Helen Collins, M.D. | CHIEF MEDICAL OFFICER | 06 Feb 2025 | 171,000 | 171,000 | - | - | Stock Option (right to buy) | ||
| Enliven Therapeutics Inc | Dr. Helen Collins, M.D. | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 18 Oct 2024 | 816 | 816 | - | 2.5 | 2,024 | Common Stock |
| Enliven Therapeutics Inc | Dr. Helen Collins, M.D. | CHIEF MEDICAL OFFICER | 18 Oct 2024 | 816 | 266,268 | - | - | Stock Option (right to buy) | ||
| Enliven Therapeutics Inc | Dr. Helen Collins, M.D. | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 30.00 per share. | 18 Oct 2024 | 816 | 0 | - | 30.0 | 24,482 | Common Stock |
| IO Biotech Inc | Helen Collins | Director | 06 Jun 2024 | 45,642 | 45,642 | - | - | Stock Option (Right to Buy) | ||
| Kura Oncology Inc | Dr. Helen Collins, M.D. | Director | 05 Jun 2024 | 26,000 | 26,000 | - | - | Option to purchase common stock | ||
| Enliven Therapeutics Inc | Dr. Helen Collins, M.D. | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 11 Apr 2024 | 20,000 | 20,000 | - | 2.5 | 49,600 | Common Stock |
| Enliven Therapeutics Inc | Dr. Helen Collins, M.D. | CHIEF MEDICAL OFFICER | 11 Apr 2024 | 20,000 | 267,084 | - | - | Stock Option (right to buy) | ||
| Enliven Therapeutics Inc | Dr. Helen Collins, M.D. | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 25.07 per share. | 11 Apr 2024 | 20,000 | 0 | - | 25.1 | 501,478 | Common Stock |
| Enliven Therapeutics Inc | Dr. Helen Collins, M.D. | CHIEF MEDICAL OFFICER | 13 Feb 2024 | 185,000 | 185,000 | - | - | Stock Option (right to buy) | ||
| Kura Oncology Inc | Dr. Helen Collins, M.D. | Director | 31 May 2023 | 26,000 | 26,000 | - | - | Option to purchase common stock | ||
| Enliven Therapeutics Inc | Dr. Helen Collins, M.D. | Chief Medical Officer | 04 Apr 2023 | 206,000 | 206,000 | - | - | Stock Option (right to buy) | ||
| Enliven Therapeutics Inc | Dr. Helen Collins, M.D. | Chief Medical Officer | 23 Feb 2023 | 287,084 | 287,084 | - | - | Employee Stock Option (right to buy) | ||
| Kura Oncology Inc | Dr. Helen Collins, M.D. | Director | 21 Jun 2022 | 23,000 | 23,000 | - | - | Option to purchase common stock |